๐ŸŽ Black Friday: up to 50% off of annual plans
Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA ยท Real-Time Price ยท USD
0.8989
-0.0111 (-1.22%)
At close: Nov 20, 2026, 4:00 PM EST
0.8800
-0.0189 (-2.10%)
After-hours: Nov 20, 2026, 7:45 PM EST
โ† View all transcripts

3rd Annual Guggenheim Healthcare Innovation Conference

Nov 10, 2026

Summary

TIMI 78 showed baseline-linked triglyceride reductions, reaching 70%-72% at high dose in patients above 500 mg/dL, with no glucose increase signal. 2027 brings Phase II catalysts in both programs; the $225M PIPE is expected to fund operations through mid-2028 and enable both Phase III starts.

Seamus Fernandez
Senior Managing Director, Guggenheim

Welcome to Guggenheim's, I guess, this is our Third Annual Healthcare Innovation Conference here in Boston. Really pleased to be joined by Marea Therapeutics. The, I guess, active ticker for the time being is under Lisata. But really pleased to have the team here. To my immediate left is Josh Lehrer. He's CEO of Marea, President and COO of Lisata. And Ian Clements is immediately to his left. He's CFO. We've asked Josh to kind of provide an overview of the company because, as a reverse merger, I think there's an opportunity to learn more. But excitingly, there were data just presented at the American Heart Association for their ANGPTL4 antibody, and I think that really is particularly exciting because there was a New England Journal of Medicine article associated with it as well. I'll turn it over to Josh to kind of kick it off.

Josh Lehrer
CEO, Marea Therapeutics

Great. Thanks, Seamus, and thanks for having us here. It's great to be here. We're not even completely through this reverse merger, and we're in the fortunate position of having two molecules that have initial clinical validation and look like drugs, both first-in-class . We're very excited. I'll give you a quick overview on our programs, and then we can kind of touch on the reverse merger financing. Our lead program is a first-in-class antibody directed to ANGPTL4. This is a target with very strong human genetic validation, well-understood biology. It's in the same family of targets as ApoC-III and ANGPTL3, other lipid-related targets. And we're developing this for a large group of patients who have severely elevated triglycerides, severe hypertriglyceridemia.

And where we think that this could be really compelling and address an unmet need is because these patients are both at risk of pancreatitis, but also mostly have diabetes, and many have established coronary artery disease. So, we have an opportunity, we think, to have a differentiated product that can be comparable to the type of really groundbreaking efficacy on triglyceride lowering seen with the ApoC-III class, but really completely avoiding the dysglycemia and the worsening diabetes and cardiovascular risk factors, which have been seen as a class effect with the ApoC-III drugs. And the data that we'll get to that was presented at AHA goes a long way towards establishing that profile that we think could address a large group of these patients and ultimately have a significant share of what's projected to be over a $10 billion market in the U.S.

And then our second program is an endocrine program, and this is a first-in-class antibody targeting the growth hormone receptor. Investors are probably aware of the Crinetics' paltusotine program that was also to address these patients. The main thing to know about this program is that the majority of patients with acromegaly require chronic lifelong medical therapy with the goal of controlling the disease and normalizing IGF-1, and most patients never achieve a normal IGF-1 level.

That's because the drugs that are in the class of paltusotine, the somatostatin receptor ligands, it's only a minority of patients who respond. About 1/3 of patients respond. We have an opportunity with a drug that's in a different class that's already really validated by a commercial product. The target is validated, but with a much better profile, potentially. We think we could be best in class and address double the number of patients, actually, that are treated by SRLs right now, and that's a big unmet need, and it's also a big opportunity. About $1 billion total in the U.S., projections for the U.S. somatostatin receptor ligand market for acromegaly, and we think that we could address twice the number of patients of the SRL class.

Seamus Fernandez
Senior Managing Director, Guggenheim

Great.

Josh Lehrer
CEO, Marea Therapeutics

Then on the kind of what's coming next, 2027 will be a big year for us. We'll be, I mean, we can kind of get to this in more detail, but we'll have kind of an important additional clinical catalyst for both programs, and we're also working on a pipeline with next-generation programs that follow our lead program.

Seamus Fernandez
Senior Managing Director, Guggenheim

Great. Maybe we can just kind of go through yesterday at AHA, you presented the title, TIMI 78 data as a late breaker . Maybe just walk us through the key findings. I think in particular, the 40% triglyceride reduction overall, but the way triglyceride lowering actually scaled with baseline triglycerides was uniquely interesting.

Josh Lehrer
CEO, Marea Therapeutics

Yeah. I know this is a conversation with someone, it's easier to kind of-

Seamus Fernandez
Senior Managing Director, Guggenheim

Yeah, it's easier to look at.

Josh Lehrer
CEO, Marea Therapeutics

-see visually than to talk about lots of numbers. R eally, the main thing we learned in this study that we didn't know before was this pretty dramatic scaling of efficacy or of triglyceride lowering with baseline, the baseline triglyceride level. We published data from a phase II-A study last year in The Lancet in patients who had lower, moderate elevations in triglycerides, mostly under 300 mg. So, kind of what you see on the far left of this slide, and we saw about 40% lowering, and we see that again. But what's new is that we also had patients in this study that covered a wide range. And we had some patients who had severe elevations, over 500 mg. And when we break down the participants in this study by baseline level, what was really encouraging for us is to see this really scaled efficacy.

Going from about 35%, near 40%, at the high dose in patients who are under 300 mg per deciliter to about 45% in patients who are 300 mg to 500 mg. And then, in our target patients going forward- with triglycerides over 500 mg, we're seeing the efficacy go up to 70%, 72% at the high dose. And that is very much comparable to what's been seen in terms of change from baseline with the ApoC-III class. And the reason that's important for these patients is that to really remove the risk of pancreatitis, you want to get patients below 500 mg.

And if you deliver this kind of mean reduction, you're going to be moving the vast majority of patients below 500 mg, and that's translated into clinical pancreatitis benefit with the ApoC-III inhibitors. The other important result is that we saw a very clean profile.

Really no safety or tolerability concerns, and very specifically, no evidence of an increase in glucose in the diabetic patients. We had a lot of diabetic patients in this study, and from prior studies, we see none of the liver fat signal that's been seen with members of the ApoC-III class.

Seamus Fernandez
Senior Managing Director, Guggenheim

Interesting. What about remnant cholesterol, other potential results from the study itself?

Josh Lehrer
CEO, Marea Therapeutics

Remnant cholesterol also, we saw reductions that were very consistent and in line with the triglyceride lowering. That remnant cholesterol is kind of thought to inform on cardiovascular risk and residual risk. For sHTG specifically, it's really the triglycerides that we're focusing on. The remnant cholesterol endpoint was there because we had also been considering kind of the larger ASCVD and CV risk reduction indication for this molecule. The genetics are very strong there. And that, I think, is still a potential sort of life cycle management or future option to expand into for this molecule and for this target.

Seamus Fernandez
Senior Managing Director, Guggenheim

Yeah. And just in terms of that sort of scaled efficacy, can you just help us understand, what is it about this mechanism that is resulting in what looks like kind of scaled efficacy? Typically, when we look at LDL-lowering therapies, you see PCSK9 will do somewhere between 50% and 60%-

Josh Lehrer
CEO, Marea Therapeutics

Right.

Seamus Fernandez
Senior Managing Director, Guggenheim

-almost regardless of baseline.

Josh Lehrer
CEO, Marea Therapeutics

T hat's right. T ypically, what you see is the absolute change goes up, and the relative change is pretty similar. That is actually what you see with the ApoC-III class. If you treat normal, healthy volunteers with ApoC-III inhibitor, you'll cut the normal triglycerides in half.

That's not true here, and there are some unique aspects of this target and actually of the genetics. What's different about ANGPTL4 compared to the other targets is that its action is really in the adipose tissue, and it's very specific for one particular lipase that hydrolyzes triglycerides, and it's heavily induced.

It's a gene that's regulated by PPAR-gamma. As free fatty acids are induced and go up, the levels of ANGPTL4 can go up by 10 or 20-fold, compared to other targets that are pretty constantly expressed, really across the range. The Lisata hypothesis is that this is kind of causing the most problem in the sickest patients.

The levels of ANGPTL4 go up along with triglycerides, and then we have an opportunity, more target to knock down, and then that's why we see the greater efficacy.

Seamus Fernandez
Senior Managing Director, Guggenheim

Got it. Okay, great. The key differentiation here, it really seems like, is a very, very clean metabolic profile. You mentioned sort of most patients in the sHTG population already have diabetes or are pre-diabetic, but maybe you can put some numbers around that to help us understand it a little bit better.

Josh Lehrer
CEO, Marea Therapeutics

I think just to begin with, we think that the data on the ApoC-III drugs is really compelling. Ionis is now doing the hard work of building the market-

Seamus Fernandez
Senior Managing Director, Guggenheim

Yeah.

Josh Lehrer
CEO, Marea Therapeutics

-and addressing those patients. The efficacy that's seen, the clinical benefit is really transformative for these patients. Where we see the opportunity, and really what we have heard back from physicians in market research, is that, while the glucose increases that have been seen with the ApoC-III class and the liver fat signal that has been seen is not a showstopper. High-risk patients are going to get these drugs because they need them to prevent these really bad pancreatitis events.

That if there's an alternative available that doesn't worsen glycemic control, doesn't cause pre-diabetics to become diabetic, doesn't cause diabetic patients to need to go on insulin and become more difficult to manage, that especially in patients who already have diabetes, that's going to be preferable. Because the fraction of sHTG patients with diabetes, if we look back to the phase III CORE 1, CORE 2 study, it was 60%-70%. So it's the majority of these patients have diabetes. We think that this is a compelling differentiated profile for a large chunk of the patients who need these therapies. When we've thought forward to how this could play in the landscape, we think that largely it will be in new starts.

What we've heard is that all things being equal in diabetic patients for new starts, this would be the number one choice for a diabetic patient.

Seamus Fernandez
Senior Managing Director, Guggenheim

Got it. If I look at the, what's encouraging is with the dose response, you see this confidence interval kind of tightening up across the board, but in particular in the over 500 mg group, despite a small number of patients in there.

Josh Lehrer
CEO, Marea Therapeutics

Right.

Seamus Fernandez
Senior Managing Director, Guggenheim

Can you talk a little bit about your confidence as you advance into your phase II programs to kind of prove out the data next year, just how you're conducting the phase II, your confidence in that sort of 70% reduction in that patient population?

Josh Lehrer
CEO, Marea Therapeutics

T he caveat, of course, is that these are small numbers. This was not designed as a pure sHTG study. Part B of this study will be a pure sHTG study, so that'll be the data that's coming next year.

But I think what's really encouraging to us is really two things. One is this trend across the data set, and we see this clear correlation between baseline triglycerides and then effect size. We see this really across the board, and that's in all across the 230+ patients in the study. Then specifically, in the dozen patients here who had triglycerides over 500 mg, while it is small numbers, it's precisely those error bars. If we kind of drill down into that further, we saw that actually every single patient that was in the middle or high dose group had a reduction in the range of 60%-80%.

I think we can be as confident as we can be until we've done bigger studies that with more numbers, we'll be somewhere in that range of 60%-80%, and I think that's really the target.

Seamus Fernandez
Senior Managing Director, Guggenheim

Yeah.

Josh Lehrer
CEO, Marea Therapeutics

To be comparable to the ApoC-III class.

Seamus Fernandez
Senior Managing Director, Guggenheim

You mentioned some of the distribution is to adipose tissue. What is interesting is, if we see some hepatic fat forming with the ApoC-III drugs, it seems like that's one of the differentiating characteristics here, but mechanistically, is it really that the adipose tissue that's accepting the triglycerides to some degree, is predominantly subcutaneous? Is that the right way to think about it, or?

Josh Lehrer
CEO, Marea Therapeutics

I guess the first thing I would say on the differentiation, I think the strongest thing we've heard is really around the dysglycemia.

Seamus Fernandez
Senior Managing Director, Guggenheim

Yeah. Okay.

Josh Lehrer
CEO, Marea Therapeutics

Why is that seen with the ApoC-III class, and why are we not seeing it here? The hypothesis, and this has actually been talked about in the discussion of the New England Journal publications for the ApoC-III drugs-

Seamus Fernandez
Senior Managing Director, Guggenheim

Yep.

Josh Lehrer
CEO, Marea Therapeutics

-as well as in the recent publication for ours, is thought to be kind of where the fat goes, where the triglyceride goes. Both types, both drugs, both inhibition of both targets clear triglycerides from the blood. With ApoC-III, those triglycerides are largely flowing to the liver or liver and muscle, and with ANGPTL4 inhibition, those triglycerides are really flowing to the adipose tissue. We think of this as kind of putting fat where it belongs.

Seamus Fernandez
Senior Managing Director, Guggenheim

Right.

Josh Lehrer
CEO, Marea Therapeutics

If there's one place to put fat, it's probably in healthy adipose depots.

Seamus Fernandez
Senior Managing Director, Guggenheim

Okay.

Josh Lehrer
CEO, Marea Therapeutics

By offloading triglyceride delivery to the liver, at least the biological hypothesis that makes a lot of sense, is that you're avoiding the potential for ectopic fat being deposited in the liver.

Seamus Fernandez
Senior Managing Director, Guggenheim

Yeah.

Josh Lehrer
CEO, Marea Therapeutics

You're avoiding kind of flooding the hepatocytes with fatty acids that would make them metabolize less glucose-

Seamus Fernandez
Senior Managing Director, Guggenheim

Okay.

Josh Lehrer
CEO, Marea Therapeutics

-as a consequence.

Seamus Fernandez
Senior Managing Director, Guggenheim

Understood. In terms of just the estimate of the market opportunity, I think one of the dynamics of being a potential third entrant with a differentiated profile is you get the benefits of somebody else helping to build the market. So how are you thinking about that, and what are you watching for in terms of the key market sort of building characteristics over time? I guess our view is that with a good commercial team, an effective commercial team, you still are probably going to have a look and feel of LEQVIO to some degree. Is that a reasonable way to think about it?

Josh Lehrer
CEO, Marea Therapeutics

I think another way of saying it is it's going to take time.

Seamus Fernandez
Senior Managing Director, Guggenheim

Yeah.

Josh Lehrer
CEO, Marea Therapeutics

I think we-

Seamus Fernandez
Senior Managing Director, Guggenheim

Incidentally, LEQVIO is tracking to be a $5 billion-

Josh Lehrer
CEO, Marea Therapeutics

Right

Seamus Fernandez
Senior Managing Director, Guggenheim

-drug.

Josh Lehrer
CEO, Marea Therapeutics

Right. W e feel that it's a nice position to be in to have Ionis. Then we expect Arrowhead next year, which deserve a lot of credit for really developing these effective drugs and also doing a lot of work to establish the market. I think that what we're looking for, I think that really the positive part of the story is that there's a lot of interest from physicians. There seems to be a lot of demand from physicians, and there's also broad coverage to the label.

Seamus Fernandez
Senior Managing Director, Guggenheim

Yeah. Great. And then just beyond sHTG, other opportunities, mixed dyslipidemia, mixed hypertriglyceridemia, remnant cholesterol, other targets. Obviously ASCVD, a very costly-

Josh Lehrer
CEO, Marea Therapeutics

Yeah.

Seamus Fernandez
Senior Managing Director, Guggenheim

-sort of future potential development opportunity once you're generating lots of

Josh Lehrer
CEO, Marea Therapeutics

W e can talk about sort of the resources and capital we have now, but we're well-financed, but we're also a small company, and we're really laser-focused on this initial indication in sHTG.

Seamus Fernandez
Senior Managing Director, Guggenheim

Yeah.

Josh Lehrer
CEO, Marea Therapeutics

The genetics and biology with ANGPTL4 are continuing to be very exciting around coronary disease. It's one of the most well-validated genetic targets that hasn't been pursued yet. That's something I think we would not do on our own.

Seamus Fernandez
Senior Managing Director, Guggenheim

Yeah.

Josh Lehrer
CEO, Marea Therapeutics

It's also something we could consider with some of the pipeline programs. We do have siRNA adipose-directed programs where we're planning on developing a next-generation version of this ANGPTL4 monoclonal with an siRNA, and that could be a molecule that we could think with a partner about expanding to bigger indications.

Seamus Fernandez
Senior Managing Director, Guggenheim

Got it. Let's talk about acromegaly. Just remind us, I mean, we talked a little bit about the unmet need, but how are you thinking about it? I think there's roughly 30,000 U.S. patients affected. More than half, at least in our research, experts we've talked to suggest that half are still uncontrolled. Maybe just kind of give us the lay of the land on the sort of treatment opportunity that you see ahead.

Josh Lehrer
CEO, Marea Therapeutics

T hat's about 30,000 patients, and it tends to be underdiagnosed. I think Crinetics and now Vertex is doing work to really expand identification of these patients. And generally, after surgery, really, these patients are managed by measuring IGF-1 levels, which reflect how much excess growth hormone signaling is going on. Tracks very well with symptoms. If IGF-1 is elevated, they have early mortality, actually from cardiovascular events, can have bad diabetes, joint pain. So, it's a very symptomatic, morbid disease if you don't control IGF-1. So, there's a strong drive to treat to IGF-1 goals. And the reason that, as you said, the majority of these patients never get to control, is because of limitations of medical therapy. The somatostatin receptor ligands, there are many good options, injectables, depot monthly injections, and now an oral paltusotine that can get patients to control.

The problem is that the response rates are only about 1/3 of patients, and that's a biological issue. That's because many patients, their tumors express low levels of the somatostatin receptor. So, many patients, those drugs just won't get them to normalization. And in contrast, there is an available drug commercially from a different class. It's a drug from Pfizer called pegvisomant that directly blocks the receptor downstream, and that achieves effective control in over 80% of patients in clinical trials. So, it's actually a very effective drug, but in the real world, it doesn't deliver on that promise because patients just can't stick with it. We kind of mentioned some of the limitations, safety, tolerability, dosing, daily dosing, reconstitution from a vial.

What we think an optimal direct growth hormone antagonist can do is to address those 2/3 of patients who don't get to IGF-1 control on the somatostatin receptor ligand class. To do that, the goal is pretty simple. It's to deliver efficacy, and I can put this slide up here. Deliver efficacy on IGF-1 lowering that is comparable to what's been seen with this effective Pfizer product, this competitive antagonist-

Seamus Fernandez
Senior Managing Director, Guggenheim

Yeah.

Josh Lehrer
CEO, Marea Therapeutics

-with pegvisomant, but to do that with much better dosing, much better durability, and without the LFT elevations and injection site reactions that have been seen with that drug. We actually just started dosing in a phase II study, so of course, we'll be getting more data. But the nice thing here is that even in healthy volunteers, this is data from phase I, we can look at IGF-1 suppression and benchmark that to what was seen with pegvisomant and understand that we're right where we need to be. This is showing kind of different dose groups. It's showing IGF-1 levels over time. That red dotted line shows kind of the highest effect that was seen in healthy volunteers with pegvisomant, 49%.

We're easily achieving that. We're actually exceeding that with multiple doses. So, that gives us a lot of confidence. Based on this very long duration of effect that you can see on this slide, we're anticipating that in patients, we should be at a biweekly injection subQ. The goal will be an auto-injector. T ransformative from what patients, from the options they have today, patients who don't get control on SRLs.

Seamus Fernandez
Senior Managing Director, Guggenheim

You dosed the first patient in the phase II in October. Just maybe quickly walk us through the design, versus placebo. You've got a loading dose, but maybe just the timing of when we see the data and what success looks like.

Josh Lehrer
CEO, Marea Therapeutics

L argely we'll be looking to reproduce these effects. We know that with these other drug classes that what you see in healthy volunteers predicts what you see in patients, and that's what we'll be looking to confirm. IGF-1 lowering happens fast, so we don't need a lot of time. So, we'll have a 10-week endpoint. We're doing a loading dose just to make sure that we've gotten to steady state by 10 weeks. We don't anticipate that a loading dose is necessarily going to be required in phase III or commercially. Then we're looking at three, we're dosing biweekly, and we're looking at three dose levels bracketing what we expect to be the clinical dose, at least for most patients, of 300 mg. Then looking at IGF-1 at 10 weeks.

We'll be including actually patients who are on background therapies like paltusotine, other SRLs that have gotten partial responses but not a goal yet. So, we'll be looking at this both in a monotherapy setting in washout patients or naive patients, as well as added on to SRLs. That's how we also expect to design the phase III to support a broad label.

Seamus Fernandez
Senior Managing Director, Guggenheim

Yeah. Interesting. Just the market opportunity, how are you looking at it? You said $1 billion . Is there an opportunity for potentially a bigger market opportunity than that from your perspective, like to unlock more patients?

Josh Lehrer
CEO, Marea Therapeutics

I think that a kind of a relevant number is the projections for the SRL class, which are really just talking about the 1/3 of patients who respond. That's projected to be $1 billion in aggregate.

With increased diagnosis, increased awareness, Vertex at least believes that could grow significantly. Just based on the addressable patients, whatever the SRLs can address in aggregate, we think this class and this mechanism can address double that, just based on the response rate. So, whatever the SRL market grows to, we think this potentially could be double that.

Seamus Fernandez
Senior Managing Director, Guggenheim

Got it. Ian, you've got the $225 million private placement. Maybe just remind us what that funds in terms of operations, and then beyond that, the opportunities for some of these catalysts to really drive incremental optionality.

Ian Clements
CFO, Marea Therapeutics

I think that a great result in terms of bringing some fantastic investors into the PIPE to support us through the next, into the middle of 2028, basically. As you can see on the slide here, I think, and as Josh has kind of alluded to as well, a number of catalysts during this time period across MAR001. We're looking at the selection of the dose for our half-life-extended version that we would ultimately take into phase III, and actually getting the data from that cohort of patients with sHTG as well by the end of next year. Turning to acromegaly, having interim data from the phase II study that Josh outlined the design of, as well as by the end of the year, having the full proof-of-concept data set in that phase II.

Within that timeframe as well, with the capital that we raised, actually also being able to start both of the phase IIIs with sHTG and in acromegaly as well.

Seamus Fernandez
Senior Managing Director, Guggenheim

Well, that's a lot to do in a relatively short period of time, but some huge catalysts in 2027. Exciting times. Thanks for spending the time with us today, and obviously we're looking forward to the future of Marea.

Ian Clements
CFO, Marea Therapeutics

Excellent.

Josh Lehrer
CEO, Marea Therapeutics

Great. Thanks, Seamus.

Ian Clements
CFO, Marea Therapeutics

Yeah. Thanks, Seamus. Appreciate it.